Glioblastoma multiforme (GBM) is a highly proliferative cancer with generally poor prognosis and accumulating evidence has highlighted the potential of long noncoding RNAs (lncRNAs) in the biological behaviors of glioma cells. This study focused on the identification of lncRNAs to identify targets for possible GBM prognosis. Microarray expression profiling found that 1,759 lncRNAs and 3,026 messenger RNAs (mRNAs) were upregulated, and 1932s lncRNA and 2,979 mRNAs were downregulated in GBM.
| INTRODUCTION
The highly proliferative and invasive hallmarks of glioblastoma account for its dismal prognosis. The life expectancy of patients with glioblastoma multiforme (GBM) is approximately 15 months from the time of diagnosis (Stupp et al., 2005) . The World Health Organization (WHO) classification of central nervous system tumors aids in the evaluation of histological histopathology and provides prognostic predictions for patients but has limitations when used alone (Antal et al., 2015; Weller et al., 2013) . A number of studies have revealed that novel molecular targets contribute to the increased accuracy in diagnosis and the classification of primary brain tumors, as well as increasing the effectiveness of therapeutic treatment decisions (Weller et al., 2013) . Nevertheless, molecular markers are mostly focused on proteins assisting glioma assessment in modern neuro-oncology.
The genes are transcribed into messenger RNA (mRNA), which are then translated into proteins that are ultimately responsible for all cellular functions. However, long noncoding RNAs (lncRNAs) also play important roles in normal physiological processes and can contribute to human diseases, such as cancer (Mendell, 2016) , and glioma is no exception. Actually, only 1.5% of human genome DNA pairs are responsible for encoding proteins (Mendell, 2016) . Noncoding RNAs (ncRNAs) are potential targets for disease treatment and drug discovery (Matsui & Corey, 2017) . These transcripts are distributed in many organs, yet the functions of few ncRNAs are illuminated. Recent work studying the molecular mechanisms of lncRNAs has provided new insights into how lncRNAs control cellular function by coordinating regulatory proteins, localizing to target loci, remodeling chromatin architecture, RNA stabilization and transcription regulation, including enhancer-associated activity, and so forth lncRNA (MALAT1) was first discovered in metastatic lung cancer cells (Ji et al., 2003) . Gutschner, Hammerle, and Diederichs (2013) evaluated MALAT1 expression associated with metastasis and reduced patient survival; MALAT1 inhibition resulted in the reduction of cell proliferation, migration, and invasion capacity.
Yang et al described that two lncRNAs, PRNCR1 and PCGEM1, that activated androgen receptors and enhanced androgenreceptor-associated transcriptional programs promoted cancer growth (Schmitt & Chang, 2013) . Recently, the discovery of lncRNAs and related studies are increasing in major biological processes including evolution, development, metabolism, and oncogenesis (Wang et al., 2016) . Uncovering cancer-associated lncRNAs would reveal a new level of the tumor progression mechanism. Therefore, comprehensive studies on specific lncRNA expression patterns should be encouraged.
This study explored the specific expression patterns of lncRNAs in the human brain malignant glioma cell line U251 and profiled the lncRNAs and mRNA expression signatures. TCONS_00020456 was chosen as the focus, and the specific effect of TCONS_00020456 on glioma cells was evaluated by functional in vitro and in vivo experiments. 
| MATERIALS AND METHODS

| Patients and samples
| Cell lines and cell culture
Human glioma cell line U251, U87 (authenticated by STR profiling, Carlsbad, CA) and normal human astrocytes (HA) were cultured as previously described (Tang et al., 2018) . HAs were maintained in the astrocyte medium (ScienCell Research Laboratories, Carlsbad, CA).
Glioma cells were maintained in Dulbeccoʼs modified Eagleʼs medium (high glucose; Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen) at 37°C and 5% CO 2 in a CO 2 incubator (Thermo Fisher Scientific).
| Selecting lncRNA biomarkers
The difference between the raw processed signal across three U251 
| RNA extraction
Trizol reagent (Invitrogen, Carlsbad, CA) was used for RNA isolation.
RNA concentration and purification were determined by ultraviolet spectrophotometry (BioDee, Biotechnology Co. Ltd, Beijing, China).
| LncRNA and mRNA microarray expression profiling
LncRNA and mRNA expressions were determined using a CapitaBio 
| Glioma staining assessment
Staining score = the depth of glioma staining × ratio of stained cells.
The staining depth was divided into 0 (negative), 1 (weak positive), 2 (moderate positive), and 3 (strong positive). The proportion of stained cells was divided into 1 (1-24% positive tumor cells), 2 (25-49% positive tumor cells), 3 (50-74% positive tumor cells), and 4 (75-100% positive tumor cells). The two were multiplied to get a score of 0, 1, 2, 3, 4, 6, 8, 9, or 12. Zero was classified as negative. 1, 2, 3, and 4 were classified as weak positive, 6 and 8 were classified as moderate positive, and 9 and 12 were classified as strong positive.
2.9 | Construction of stable cell lines with overexpressed OR downregulated lncRNA-TCONS_00020456
Lenti-CAS9-sgRNA for TCONS_00020456 overexpression and vectors for knockout were constructed by GeneChem (Shanghai, China).
Stable cell lines were generated as previously described (Li et al., 2017) . U251 cells were transduced with vectors at a multiplicity of infection of 5 in the presence of 5 μg/ml polybrene. The supernatant was removed after 24 hr, and the medium with FBS was added to the U251 cells. After 72 hr, 5 μg/ml puromycin was added. The relevant empty lentivectors were employed as negative controls.
| Wound healing and transwell invasion assay
Cell migration and Transwell assay were evaluated as described previously (Li et al., 2017; Sun et al., 2018) . 
| Western blot analysis
| Nude mouse glioma model in vivo
Four-week-old female BALB/c nude mice were purchased from LinChang Biotechnology Co. Ltd. (Shanghai, China). U87 cells were infected and a single-cell suspension of 1 × 10 7 /ml U87 was prepared.
One hundred microliters were subcutaneously injected into the left axillary of the nude mice. Groups consisted of the control, overexpression (OE), and Konck-Down (KD) groups. Tumors were observed on the 18th day and were allowed to grow for another 22 days until the tumor diameter reached approximately 1.2 cm with a total volume of 1.5 cm 3 . The short and long tumor diameters were recorded with vernier callipers. Tumor volume was calculated as V = diameter length × short radius 2 , centimeter). The downregulated genes were mainly associated with cellular extravasation response.
Gene set analysis mapping of the 6,005 differentially regulated genes identified the top 30 biological pathways of upregulated mRNAs and downregulated mRNAs (Figure 2c,d) . The most significant pathways targeted by upregulated and downregulated mRNA transcripts were involved in GBM pathogenesis.
| Confirmation of differentially expressed lncRNAs from microarray data
Twelve upregulated lncRNAs and 26 downregulated lncRNAs from the microarray analysis were selected and assessed by reverse transcription PCR (RT-PCR; Table S2 ). RT-PCR results showed that four significantly upregulated lncRNAs and 21 downregulated lncRNAs in U251 glioma cells compared with normal HAs (Table S3 ; Figure 3b ). Twenty-five lncRNAs were input into the cancer genomics cBioportal and 17 lncRNAs interacted positively with mRNA ( Figure 3a ). LncRNA 
| TCONS_00020456 expression level correlated with glioma grades
Different WHO grades of tumor tissue were subjected to TCONS_00020456 expression analysis (Figure 4 ). TCONS_00020456
expression was significantly correlated with the pathological grades.
TCONS_00020456 expression decreased in high WHO grades compared with lower grades (Figure 4a ). Immunohistochemistry combined with RNA FISH assay also demonstrated that TCON stained with HRP is expressed mainly in low-grade gliomas. The image of low-grade glioma showed more dark brown areas apparently (Figure 4b ). In addition, we further explored whether pathological types of glioma interfere with the correlation outcome.
It was gratifying to get the nonsignificant result, which indicates that the level of TCONS_00020456 was related to the WHO grades of glioma but not the pathological types (Table 1) .
3.5 | Decreased TCONS_00020456 expression indicated a short life span and was a prognostic factor when combined with WHO grade
The cut-off value for distinguishing between WHO grades were 3.5, which showed relatively high sensitivity of 87.1% (95% CI: 71-96%), and specificity of 92% (95% confidence interval [CI]: 62-99%; Figure   4c ). Comparison between IV and I, III and I, and II and I, resulted in an area under the ROC curve of 0.90, 0.90, and 0.70, respectively.
Further survival analysis was based on these values. High-grade glioma patients with lnc less than 3.5 had a shorter survival period, suggesting a potential link between a low lnc expression level and human highgrade glioma progression (Figure 4d ). Death was regarded as the outcome variable, and logistic regression results are shown in Table 2 .
The lnc level coupled with WHO grade is of high value in prognosis determination in spite of marginal significance. 
| TCONS_00020456 negatively promotes glioma progression in vivo
Increased tumor sizes were observed in the lncRNA-KD group
(1.552 ± 0.235 g) compared with those in the LV-vector group (0.924 ± 0.164 g) on the last day. Additionally, decreased tumor sizes were observed in the lncRNA-OE group (0.332 ± 0.078 g) compared with those in the LV-vector group (Figure 6a,b) . As a whole, the difference in tumor size was apparent over time. Tumor weight was covariant with tumor size (Figure 6c,d) . These results demonstrate that TCONS_00020456 inhibited glioma progression in vivo. Furthermore, immunohistochemical showed that knockdown of lncRNA promoted the expression of Smad2 and PKCα in tumors (Figure 6e,f) , consistent with the in vitro results (Figure 5f ) and Oncomine database (Figure 5r,s) .
| Biological information analysis of TCONS_00020456
Biological information analysis provided a total of 13 miRNAs considered common targets of TCONS_00020456, Smad2, and PKCα collectively (Figure 7) , and the RACE preliminary experiment showed that TCONS_00020456 had high specificity in glioma cells (Figure 7a) . Figure 7b ). After continuous sequence alignment, only one miRNA met the criteria (hsa-miR-1279; Figure 7c ).
| DISCUSSION
Our study represents the first analysis of lncRNA-TCONS_00020456guided regulation of Smad2 and PKCα in GBM. TCONS_00020456 was markedly decreased in human GBM, and low TCONS_00020456 expression was significantly associated with a higher WHO grade and shorter overall survival in GBM. TCONS_00020456 was coexpressed with Smad2 and PKCα mRNAs. TCONS_00020456 downregulation aggravated cell migration, invasion and EMT of glioma cells through an interaction with Smad2 and PKCα. Smad2 is a core component of transforming growth β (TGF-β)/Smad which contributes to the progress of EMT in cancer (Song et al., 2019) .
LncRNAs are a class of ncRNA containing more than 200 nucleotides that were initially considered transcriptional noise (Deniz & Erman, 2017) . LncRNAs are involved in protein modification and metabolism, recruitment of transcription factors, and cell cycle control (Huarte, 2015) .
Our study showed that TCONS_00020456 may decrease Smad2 levels via mediating by miRNA (hsa-miR-1279) indirectly or complementary base pairing in mRNA directly (Figure 7 and Figure S1 ). Although it is only a prediction, it is enough to indicate a research direction for our further mechanism exploration. EMT is a crucial event in the metastatic process that endows tumor cells with the ability to leave the primary tumor mass 
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Jackson, & Thiery, 2016) . EMT is triggered and maintained by the TGF-β signaling pathway (Thiery, 2002) . Coincidently, Smad2 participates in promoting transcriptional activation of EMT related transcription factors:
Snail1, Slug, ZEB1/2, Twist1/2, and Sox4 (Budi, Duan, & Derynck, 2017; Macias, Martin-Malpartida, & Massague, 2015) . In our study, we checked the expression of effector proteins in EMT. EMT involves multiple components, such as vimentin and E-cadherin (Mima et al., 2013) .
Vimentin is a well-known metastasis marker whose expression is a late event in EMT that leads to the upregulation of mesenchymal genes (Kokkinos et al., 2007) . E-cadherin, which suppresses the malignant metastasis and invasion of epithelial cells, is related to the invasiveness of glioma cells (Shi et al., 2013) . This study found that E-cadherin and vimentin levels changed with changing lncRNA levels, indicating Smad2 as a promising target molecule of TCONS_00020456.
The other protein regulated by TCONS_00020456 in this study is PKCα. PKC family comprises a series of phospholipid-dependent serine-threonine kinases (Nishizuka, 1988 ) that play important roles in signal transduction and in the regulation of cell growth, differentiation, and apoptosis (Mandil et al., 2001) . The PKCα signaling pathway has been widely studied in malignant gliomas, and PKCα activity was increased in gliomas and glioma cell lines (Couldwell, Antel, & Yong, 1992) . Our study corroborated these findings, as the level of PKCα increased in glioma sample tissue. Moreover, it is proved that the inhibition effect of PKCα inhibitor (GF1029203X) on glioma is greatly enhanced, including migration and invasion ( Figure S2 ). Corresponding to the low level of TCONS_00020456, PKCα increased significantly in glioma cells that contribute to cell proliferation (Hussaini et al., 2000; Mandil et al., 2001) .
Interestingly, PKCα has a bidirectional regulation function and can act either as an oncogene or as a tumor suppressor gene (Antal et al., 2015; Newton & Brognard, 2017 PKCα was overexpressed in breast cancer, and inhibited apoptosis and contributed to chemoresistance via the ERK signaling pathway (Pal & Basu, 2017) . PKCα phosphorylation participates in the downstream activation of the NF-κB pathway, which contributes to the development of multiple types of cancers. In human melanoma, the ERK signaling pathway upregulates JNK and activates the c-Jun oncogene and its downstream targets, including RACK1 and cyclin D1 (Lopez-Bergami et al., 2007) . Furthermore, abnormally activated RAS proteins are the main oncogenic driver that governs the function of major signaling pathways involving ERK and protein kinase C (Khan et al., 2019) . Thus, uncontrolled transcriptional expression and reprogramming in carcinogenesis are also involved in ERK activation (Ward, Braun, & Shannon, 2012) . PKC cooperates with the protein Ser/Thr phosphatase, calcineurin, in transducing signals leading to JNK activation (Ghaffari-Tabrizi et al., 1999 ). In the current study, we found that ERK/JNK increased when TCONS_00020456 decreased. This signal pathway should be thoroughly explored, as the specific mechanism of lncRNA in regulating protein activity would benefit this field of study.
Inevitably, lncRNAs can exert their functions through RNA-protein interactions to modulate target genes (McHugh et al., 2015) .
Biological information analysis identified 13 miRNAs considered common targets of TCONS_00020456, smad2, and PKCα collectively ( Figure 7 ). This implies that TCONS_00020456 plays an oncogenic role in glioma by regulating miRNAs. LncRNA pull-down assays should be used to identify target molecules (DNA, RNA, and proteins), through which the relationship between Smad2 or PKCα interacting with proteins and chromatin methylation, histone modification, and gene transcription can be analyzed. Based on this assumption, the RACE preliminary experiment showed that TCONS_00020456 had high specificity in glioma cells. In future studies, the RACE experiment could be conducted to obtain the fulllength lncRNA sequence, which could identify basic molecular biological properties, including length detection, protein-coding potential analysis, intracellular distribution, and nuclear distribution.
The association suggests that lncRNA could regulate mRNA expression mediated by miRNAs (Lin et al., 2015) .
In summary, our findings revealed that decreased TCONS_00020456 promotes the migration, invasion, and epithelial-mesenchymal transition of glioma cells in vitro, as well as glioma progression in vivo.
TCONS_00020456 could negatively regulate PKCα-ERK/JNK and Smad2 expression levels. From the above study, TCONS_00020456 acts as an oncosuppressor in GBM. Furthermore, decreased TCON expression demonstrated a short life span and it could be a potential prognostic biomarker. However, large-scale clinical validation is still needed.
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